Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Net Income of $4.50 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $4.50B | +2.1% |
| 2024 | $4.41B | +11.6% |
| 2023 | $3.95B | -8.9% |
| 2022 | $4.34B | -46.3% |
| 2021 | $8.08B | +129.9% |
| 2020 | $3.51B | +66.0% |
| 2019 | $2.12B | -13.4% |
| 2018 | $2.44B | +104.0% |
| 2017 | $1.20B | +33.8% |
| 2016 | $895.50M | +40.8% |
| 2015 | $636.06M | +88.1% |
| 2014 | $338.13M | -18.3% |
| 2013 | $413.74M | -44.9% |
| 2012 | $750.27M | +438.3% |
| 2011 | -$221.76M | -112.3% |
| 2010 | -$104.47M | -54.0% |
| 2009 | -$67.83M | +14.3% |
| 2008 | -$79.13M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.46B | +8.9% | +4.9% |
| June 30, 2025 | $1.39B | -2.8% | +72.1% |
| March 31, 2025 | $808.70M | +12.0% | -39.7% |
| September 30, 2024 | $1.34B | +33.0% | -6.4% |
| June 30, 2024 | $1.43B | +47.9% | +98.4% |
| March 31, 2024 | $722.00M | -11.7% | -28.4% |
| September 30, 2023 | $1.01B | -23.4% | +4.1% |
| June 30, 2023 | $968.40M | +13.6% | +18.4% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +2.1% in Net Income compared to the prior fiscal year.
- Over the 2008–2025 period, REGENERON PHARMACEUTICALS, INC.’s net income has grown by 5793.1% (from -$79.13 million to $4.50 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: